Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma

Mañas, Adriana LU ; Seger, Alexandra LU orcid ; Adamska, Aleksandra LU ; Smyrilli, Kyriaki LU ; Siaw, Joachim T. LU orcid ; Radke, Katarzyna LU ; Muciño-Olmos, Erick A. LU orcid ; Bedoya-Reina, Oscar C. ; Esfandyari, Javanshir LU and Aaltonen, Kristina LU orcid , et al. (2025) In NPJ precision oncology 9. p.1-18
Abstract

Neuroblastoma (NB) is an aggressive pediatric solid tumor which often develops chemoresistance. Ferroptosis is a potential vulnerability in NB, but its interplay with chemoresistance and standard-of-care chemotherapy is not known. Here, we report that key antioxidant pathways are enriched in refractory NB, and that ferroptosis can be induced in NB through various mechanisms of action (MOA) in vitro and in vivo. We observed that NB standard-of-care chemotherapy can interfere with certain ferroptosis-inducing mechanisms, particularly those targeting GPX4, and that the combination of ferroptosis-inducing drugs with current clinical therapy should be based on MOA. Our work also shows that a combination of chemotherapy and the thioredoxin... (More)

Neuroblastoma (NB) is an aggressive pediatric solid tumor which often develops chemoresistance. Ferroptosis is a potential vulnerability in NB, but its interplay with chemoresistance and standard-of-care chemotherapy is not known. Here, we report that key antioxidant pathways are enriched in refractory NB, and that ferroptosis can be induced in NB through various mechanisms of action (MOA) in vitro and in vivo. We observed that NB standard-of-care chemotherapy can interfere with certain ferroptosis-inducing mechanisms, particularly those targeting GPX4, and that the combination of ferroptosis-inducing drugs with current clinical therapy should be based on MOA. Our work also shows that a combination of chemotherapy and the thioredoxin reductase inhibitor Auranofin counteracted some of the anti-ferroptotic effects of chemotherapy and the combination outperformed chemotherapy alone, resulting in increased survival in a chemoresistant NB patient-derived xenograft model. The combination of Auranofin and chemotherapy decreased the population of immature mesenchymal-like NB cells in vivo and exerted its effect through ferritinophagy, lysosome accumulation and iron overload. Thus, upon careful selection of the MOA, the inclusion of ferroptosis-inducing agents within a clinically relevant treatment protocol is feasible and can outperform standard-of-care chemotherapy in high-risk NB.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
NPJ precision oncology
volume
9
article number
311
pages
1 - 18
publisher
Springer Nature
external identifiers
  • scopus:105016535914
  • pmid:40957885
ISSN
2397-768X
DOI
10.1038/s41698-025-01090-6
language
English
LU publication?
yes
additional info
Publisher Copyright: © The Author(s) 2025.
id
82625657-8a4a-4f09-b979-171ccb09f139
date added to LUP
2025-10-08 13:26:04
date last changed
2025-11-05 16:04:20
@article{82625657-8a4a-4f09-b979-171ccb09f139,
  abstract     = {{<p>Neuroblastoma (NB) is an aggressive pediatric solid tumor which often develops chemoresistance. Ferroptosis is a potential vulnerability in NB, but its interplay with chemoresistance and standard-of-care chemotherapy is not known. Here, we report that key antioxidant pathways are enriched in refractory NB, and that ferroptosis can be induced in NB through various mechanisms of action (MOA) in vitro and in vivo. We observed that NB standard-of-care chemotherapy can interfere with certain ferroptosis-inducing mechanisms, particularly those targeting GPX4, and that the combination of ferroptosis-inducing drugs with current clinical therapy should be based on MOA. Our work also shows that a combination of chemotherapy and the thioredoxin reductase inhibitor Auranofin counteracted some of the anti-ferroptotic effects of chemotherapy and the combination outperformed chemotherapy alone, resulting in increased survival in a chemoresistant NB patient-derived xenograft model. The combination of Auranofin and chemotherapy decreased the population of immature mesenchymal-like NB cells in vivo and exerted its effect through ferritinophagy, lysosome accumulation and iron overload. Thus, upon careful selection of the MOA, the inclusion of ferroptosis-inducing agents within a clinically relevant treatment protocol is feasible and can outperform standard-of-care chemotherapy in high-risk NB.</p>}},
  author       = {{Mañas, Adriana and Seger, Alexandra and Adamska, Aleksandra and Smyrilli, Kyriaki and Siaw, Joachim T. and Radke, Katarzyna and Muciño-Olmos, Erick A. and Bedoya-Reina, Oscar C. and Esfandyari, Javanshir and Aaltonen, Kristina and Bexell, Daniel}},
  issn         = {{2397-768X}},
  language     = {{eng}},
  pages        = {{1--18}},
  publisher    = {{Springer Nature}},
  series       = {{NPJ precision oncology}},
  title        = {{Targeted ferroptosis induction enhances chemotherapy efficacy in chemoresistant neuroblastoma}},
  url          = {{http://dx.doi.org/10.1038/s41698-025-01090-6}},
  doi          = {{10.1038/s41698-025-01090-6}},
  volume       = {{9}},
  year         = {{2025}},
}